Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$128.11 0.0%	$109.27	$73.04 ▼ $128.45	$8.27B	0.84	1.30 million shs	2.99 million shs
SPRY ARS Pharmaceuticals	$18.20 +0.7%	$14.63	$8.35 ▼ $18.90	$1.79B	0.84	1.32 million shs	3.88 million shs
SRPT Sarepta Therapeutics	$17.11 -0.7%	$39.48	$16.97 ▼ $162.95	$1.68B	0.61	2.14 million shs	4.73 million shs
TLX Telix Pharmaceuticals	$16.00 -2.4%	$17.02	$13.61 ▼ $30.36	$5.41B	N/A	28,343 shs	21,786 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	-0.03%	-0.07%	+34.43%	+44.40%	+23.28%
SPRY ARS Pharmaceuticals	+0.66%	+15.19%	+22.56%	+45.72%	+125.25%
SRPT Sarepta Therapeutics	-0.70%	-14.79%	-54.04%	-75.70%	-89.10%
TLX Telix Pharmaceuticals	-2.44%	-6.71%	-5.49%	-7.19%	+1,599,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	1.7313 of 5 stars	2.1	4.0	0.0	0.0	2.9	0.8	0.6
SPRY ARS Pharmaceuticals	3.0487 of 5 stars	3.6	1.0	0.0	0.0	2.8	4.2	0.6
SRPT Sarepta Therapeutics	4.6267 of 5 stars	4.2	2.0	0.0	4.2	1.6	1.7	1.9
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.04% Downside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	70.33% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$60.88	255.79% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.00	37.50% Upside

Current Analyst Ratings Breakdown

Latest SPRY, TLX, BPMC, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
6/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$89.00 ➝ $29.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$508.82M	16.26	N/A	N/A	$4.70 per share	27.26
SPRY ARS Pharmaceuticals	$89.15M	20.05	$0.01 per share	2,149.19	$2.64 per share	6.89
SRPT Sarepta Therapeutics	$1.90B	0.88	$2.44 per share	7.02	$15.99 per share	1.07
TLX Telix Pharmaceuticals	$516.72M	10.47	$0.11 per share	140.12	$1.12 per share	14.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.09	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.56	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	33.33	N/A	N/A	N/A	N/A	N/A

Latest SPRY, TLX, BPMC, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.01	2.80	2.75
SPRY ARS Pharmaceuticals	0.30	11.00	10.74
SRPT Sarepta Therapeutics	1.00	4.02	2.46
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
SPRY ARS Pharmaceuticals	68.16%
SRPT Sarepta Therapeutics	86.68%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
SPRY ARS Pharmaceuticals	33.50%
SRPT Sarepta Therapeutics	7.70%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.25 million	N/A	N/A

SPRY, TLX, BPMC, and SRPT Headlines

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What Happened

June 27 at 12:55 PM | marketbeat.com

Telix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

June 25 at 5:06 AM | finanznachrichten.de

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?

June 23, 2025 | marketbeat.com

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

June 23, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?

June 20, 2025 | marketbeat.com

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

June 20, 2025 | globenewswire.com

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

June 19, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price Down 6.7% - Time to Sell?

June 13, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?

June 12, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares' (TLX) "Outperform" Rating Reaffirmed at Wedbush

June 12, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?

June 6, 2025 | marketbeat.com

William Blair Has Positive Estimate for TLX FY2025 Earnings

June 6, 2025 | marketbeat.com

Wedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform Recommendation

June 5, 2025 | msn.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's Why

June 5, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Now Covered by Wedbush

June 5, 2025 | marketbeat.com

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

June 3, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's What Happened

May 31, 2025 | marketbeat.com

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7, 2025 | globenewswire.com

Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX

May 7, 2025 | accessnewswire.comA

ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

May 6, 2025 | accessnewswire.comA

Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)

May 5, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, TLX, BPMC, and SRPT Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$128.11 -0.04 (-0.03%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$128.01 -0.10 (-0.08%)

As of 06/27/2025 07:00 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$18.20 +0.12 (+0.66%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$18.48 +0.28 (+1.53%)

As of 06/27/2025 07:57 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Sarepta Therapeutics NASDAQ:SRPT

$17.11 -0.12 (-0.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$17.30 +0.19 (+1.11%)

As of 06/27/2025 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$16.00 -0.40 (-2.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$16.00 -0.01 (-0.03%)

As of 06/27/2025 04:04 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time